Green tea constituent (À) epigallocatechin-3-gallate (EGCG) has shown remarkable cancer-preventive and some cancer-therapeutic effects. This is partially because of its ability to induce apoptosis in cancer cells without affecting normal cells. Previous studies from our laboratory have shown the involvement of NF-jB pathway in EGCG-mediated cell-cycle deregulation and apoptosis of human epidermoid carcinoma A431 cells. Here we show the essential role of caspases in EGCG-mediated inhibition of NF-jB and its subsequent apoptosis. Treatment of A431 cells with EGCG (10-40 lg/ml) resulted in dosedependent inhibition of NF-jB/p65, induction of DNA breaks, cleavage of poly(ADP-ribose) polymerase (PARP) and morphological changes consistent with apoptosis. EGCG treatment of cells also resulted in significant activation of caspases, as shown by the doseand time-dependent increase in DEVDase activity, and protein expression of caspase-3, -8 and -9. EGCGmediated caspase activation induces proteolytic cleavage of NF-jB/p65 subunit, leading to the loss of transactivation domains, and driving the cells towards apoptosis. EGCG-mediated induction of apoptosis was significantly blocked by the caspase inhibitor N-benzyloxycarbonylVal-Ala-Asp(OMe)-fluoromethylketone (Z-VAD-FMK), and moderately blocked by the specific caspase-3 inhibitor Z-DEVD-FMK. Further, pretreatment of cells with Z-VAD-FMK was found to suppress the cleavage of NF-jB/ p65 subunit, thereby increasing nuclear translocation, DNA binding and transcriptional activity, thus protecting the cells from EGCG-induced apoptosis. Taken together, these studies for the first time demonstrate that EGCGmediated activation of caspases is critical, at least in part, for inhibition of NF-jB and subsequent apoptosis.
Introduction
Epigallocatechin-3-gallate (EGCG), the major polyphenolic constituent present in green tea, has received much attention over the last few years, as a potential cancerchemopreventive and cancer-chemotherapeutic agent, possibly because of its wide range of effects on a number of cellular processes and efficacy in many tumor model systems (Singh et al., 2002; Chung et al., 2003; Gupta et al., 2003; Hastak et al., 2003) . Our previous studies have shown that EGCG, at pharmacologically attainable concentrations, results in inhibition of cell growth, arrest of the cell cycle in G0/G1 phase and induction of apoptosis in some human carcinoma cells (Ahmad et al., 1997) . In subsequent studies, many other laboratories reported similar findings in many other cancer cell types (Yang et al., 1998; Chung et al., 2001; Masuda et al., 2001) . The mechanism of EGCG-mediated apoptosis of cancer cells is incompletely understood. Such an understanding could be critical for developing EGCG and related compounds as agents for prevention and/or therapy of cancer.
The transcription factor nuclear factor-kappaB (NFkB) plays a critical role in the regulation of genes related to cell survival, proliferation and apoptosis (Schwartz et al., 1999; Joyce et al., 2001; Karin and Lin, 2002) . NF-kB consists of multiple members of the Rel family of proteins that include NF-kB1 (p105/p50), NF-kB2 (p100/p52), RelA (p65), RelB and c-Rel (Bours et al., 2000) . The NF-kB dimers are present in cytoplasm in an inactive form bound to inhibitory subunits, IkB (Bours et al., 2000) . Upon activation, IkB is phosphorylated, which marks the inhibitor for ubiquitination and degradation by the proteasome-dependent pathway (Aggarwal, 2000; Bours et al., 2000) . This process allows translocation of active NF-kB complexes into the nucleus, where they bind to specific DNA motifs in the promoter/enhancer regions of target genes and activate their transcription. Modulation in the transactivation domains and/or nuclear translocation of NF-kB by a variety of stimuli leads to cell cycle arrest and apoptosis (Bours et al., 2000; Joyce et al., 2001; Karin and Lin, 2002) . In recent years, considerable attention has been focused on NF-kB inhibition as a target for developing agents for cancer prevention and therapy (Yamamoto and Gaynor, 2001 ).
Several recent studies have identified the involvement of multiple caspases in the proteolytic cascade of apoptosis (Grutter, 2000; Zimmermann et al., 2001) . Caspases are synthesized as zymogens that require proteolytic cleavage to generate active enzyme subunits (Nicholson, 1999; Grutter, 2000) . These activating cleavage events are conducted by other caspases, and are thought to represent a major regulatory step in the apoptotic pathway (Nicholson, 1999; Stennicke and Salvesen, 2000) . Activated caspases cleave several target proteins including poly(ADP-ribose) polymerase (PARP) (Tewari et al., 1995) , retinoblastoma protein (Janicke et al., 1996) , cytoskeletal proteins (Lazebnik et al., 1995) , Bcl2 and Bcl-xL (Cheng et al., 1997; Clem et al., 1998) The data shown are means7s.e. of three independent experiments. Statistical analysis was performed by Student's t-test, and Po0.05 was considered significant. (b) Apoptosis was determined by cell-death ELISA PLUS , as per the vendor's protocol. Data are expressed as enrichment factors. Statistical analysis was performed by Student's t-test, and Po0.05 was considered significant. (c) DNA ladder formation. Cells were treated with the indicated dose of EGCG for 48 h, as described under 'Materials and methods'; DNA was isolated and subjected to gel electrophoresis, followed by visualization of bands. (d) Immunoblot analysis of PARP cleavage. The cell lysate was prepared following treatment, and 50 mg of protein was subjected to 12% Tris-glycine gel electrophoresis, followed by immunoblot analysis and chemiluminescence detection, as described under also identified RelA and p50 as a substrate for activated caspase (Levkau et al., 1999) . Further, cleavage of the 45 kDa subunit of DNA fragmentation factor of genomic DNA into nucleosomal fragments is the hallmark of apoptosis (Tang and Kidd, 1998) .
Studies from our laboratory and elsewhere have shown that EGCG is capable of inhibiting NF-kB activation in cancer cells Surh et al., 2001) . Recently, EGCG has been shown to modulate caspase activation (Islam et al., 2000; Hayakawa et al., 2001) . However, the relationship between caspase activation and NF-kB inhibition by EGCG is completely unknown. Here we demonstrate the essential role of caspases in EGCG-mediated inhibition of NF-kB and induction of apoptosis. The mechanism responsible for EGCG-mediated inhibition of NF-kB is the cleavage of NF-kB/p65 subunit by active caspases, and it provides evidence that this cleavage contributes to the apoptosis of human epidermoid carcinoma A431 cells.
Results

EGCG-mediated growth inhibition and apoptosis in A431 cells
Employing A431 cells, we first evaluated the effect of EGCG on cell growth by trypan blue exclusion assay. Figure 2 Time-dependent effect of EGCG on cell growth inhibition and induction of apoptosis in A431 cells. (a) Cell growth inhibition was ascertained by trypan blue exclusion assay. The data shown are means7s.e. of three independent experiments. Statistical analysis was performed by Student's t-test, and Po0.05 was considered significant. (b) Apoptosis was determined by cell-death ELISA PLUS as per vendor's protocol. Data are expressed as enrichment factors. The data shown are means7s.e. of three independent experiments, statistical analysis was performed by Student's t-test, and Po0.05 was considered significant. (c) DNA ladder formation. Cells were treated with 20-mg/ml dose of EGCG for the indicated time interval, as described under 'Materials and methods'; DNA was isolated and subjected to gel electrophoresis, followed by visualization of bands. (d) Immunoblot analysis of PARP cleavage. The cell lysate was prepared following treatment, and 50 mg of protein was subjected to 12% Tris-glycine gel electrophoresis followed by immunoblot analysis and chemiluminescence detection, as described under 'Materials and methods'. The data shown here are representative of three independent experiments with similar results Cells were treated at the indicated dose and times with EGCG, labeled with deoxyuridine triphosphate using terminal deoxynucleotide transferase and PI, by using an apoptosis kit followed by flow cytometry. Cells showing deoxyuridine triphosphate fluorescence above that of control population, as indicated by the line in each histogram, are considered as apoptotic cells, and their percentage population is shown in each box. Details are described under 'Materials and methods' section. Data shown here are from a representative experiment repeated three times with similar results
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As shown in Figure 1a , EGCG treatment (10-40 mg/ml for 24 h) of A431 cells resulted in a dose-dependent inhibition of cell growth, which was more pronounced in 20 and 40 mg/ml of EGCG treatment. To evaluate the induction of apoptosis by EGCG, we performed enzyme-linked immunoabsorbent assay (ELISA) (Figure 1b) . Compared to control, EGCG treatment resulted in significant apoptosis in A431 cells (20 and 40 mg/ml), in a dose-dependent fashion. The induction of time-dependent effect of EGCG on DEVDase activity assay. Caspase activity was measured by AFC-DEVDase assay, as described under 'Materials and methods'. Data represents means7s.e. of three independent experiments. Statistical analysis was performed by Student's t-test, and Po0.05 was considered significant. (c) Dose-dependent and (d) time-dependent effect of EGCG on protein expression of the pro-and active forms of caspase-3 and -8. For caspase-9, the antibody detects only the active form. The cell lysate was prepared following treatment, and 50 mg of protein was subjected to 12% Tris-glycine gel electrophoresis followed by immunoblot analysis and chemiluminescence detection, as described under 'Materials and methods'. The data shown here are representative of three independent experiments with similar results (Figure 1d ). In a time-dependent study, we found that a 20 mg/ml dose of EGCG resulted in a cell inhibitory response, which was significant as early as 12 h post-EGCG treatment, with an increasing trend up to 48 h of observation, as shown by trypan blue exclusion assay (Figure 2a ). The induction of apoptosis was observed by ELISA assay that showed significant apoptosis by EGCG (20 mg/ml) at 24 and 48 h post-EGCG treatment (Figure 2b) . Similarly, treatment with 20 mg/ml concentration of EGCG resulted in the formation of DNA ladder at 48 h post-treatment ( Figure 2c ). The timedependent effect of EGCG treatment was similar to that of DNA fragmentation, where a 20 mg/ml concentration of EGCG resulted in the cleavage of PARP at 48 h post-treatment ( Figure 1d ).
The induction of apoptosis by EGCG was also evident from the morphology of cells, as assessed by fluorescence microscopy, after labeling the cells with an apoptosis detection kit containing annexin V and propidium iodide (PI) (Figure 3a, b) . We used this method because it identifies the apoptotic (green fluorescence) as well as necrotic (red fluorescence) cells. As shown by the data in Figure 3a , EGCG treatment resulted in a dose-dependent apoptosis in A431 cells. The time-dependent effect of EGCG treatment was identical to that of other apoptosis parameters examined (Figure 3b ). These data indicated that EGCG treatment also resulted in necrosis of these cells, which may be a secondary event in the apoptotic process.
We next quantified the extent of apoptosis by flowcytometric analysis of EGCG-treated A431 cells labeled with bromo-deoxyuridine triphosphate and PI. As shown by the data in Figure 3c , compared to control (1.5%), EGCG treatment resulted in 8.0, 12.5 and 16.8% of TUNEL-positive cells at 10, 20 and 40 mg/ml dose. The time-dependent assay for apoptosis (20 mg/ml dose) exhibited a significant increase in TUNEL-positive cells (control 1.6 versus 6.5, 12.8 and 18.4%) at 12, 24 and 48 h post-EGCG treatment, respectively (Figure 3d ). Based on these data, we selected a dose of 20 mg/ml and 24 h post-EGCG treatment for further studies.
EGCG-induced caspase activation and increase in protein expression of caspase-3, -8 and -9 in A431 cells
To investigate the involvement of caspase(s) in EGCGmediated apoptosis, we first evaluated the caspase activity by incubating the fluorogenic peptide Ac-DEVD-AFC with the cell lysates undergoing apoptosis. The release of 7-amino-4-trifluoromethylcoumarin (AFC) was measured with a fluorescence spectrophotometer at 400-nm excitation and 505-nm emission. Treatment of A431 cells with EGCG leads to the dose-dependent activation of caspases with 1.2-, 1.7-and 1.8-fold induction at 10, 20 and 40 mg/ml, respectively (Figure 4a ). The time-dependent EGCGmediated caspase activation of A431 cells (20 mg/ml dose) was maximum (1.9-fold) at 24 h of treatment ( Figure 4b) .
We next performed immunoblot analysis of the members of group II and III caspases in the cell lysate obtained from EGCG-treated A431 cells. We have used antibodies that specifically recognize the pro-and active forms of caspases (for caspase-3, and -8). For caspase-9, we have used the antibody that recognizes the cleaved (active) product at 35 kDa. EGCG treatment of cells resulted in a dose-dependent increase in the cleaved product of casapse-3 (17 kDa), with concomitant decrease in the pro-form (32 kDa). Similarly, a dosedependent increase in the active form of caspase-8 (43 and 18 kDa) and caspase-9 (35 kDa) was observed after EGCG treatment (Figure 4c ). Further, EGCG treatment also resulted in a significant time-dependent increase in the active products of caspase-3, -8 and -9, respectively ( Figure 4d ).
Inhibition of caspases increases cell growth and inhibits EGCG-mediated apoptosis in A431 cells
The above results indicate that EGCG treatment of A431 cells results in apoptosis via activation of caspases. Since Z-VAD-FMK inhibits caspase activation, we next asked whether Z-VAD-FMK could block EGCGmediated apoptosis. Compared to EGCG treatment (10, 20 and 40 mg/ml), pre-incubation of A431 cells with Z-VAD-FMK (10 mM) 2 h before EGCG treatment resulted increases of 14.5, 18 and 12% in cell growth (Figure 5a ). These results were further confirmed by ELISA assay, where incubation of cells with Z-VAD-FMK with EGCG inhibited cell death by 16% Figure 5 EGCG-mediated cell growth inhibition and induction of apoptosis is blocked by caspase inhibitor in A431 cells. (a) Cell growth inhibition, as ascertained by trypan blue exclusion assay. Cells were incubated with 10 mM concentration of the general caspase inhibitor Z-VAD-FMK for 2 h, followed by addition of the indicated doses of EGCG. The data shown are means7s.e. of three independent experiments; statistical analysis was performed by Student's t-test, and Po0.05 was considered significant. (b) Apoptosis as determined by cell-death ELISA PLUS kit according to the vendor's protocol. Data are expressed as enrichment factors. The data shown are means7s.e. of three independent experiments. Statistical analysis was performed by Student's t-test, and Po0.05 was considered significant. (c) DEVDase activity assay. Caspase activity was measured by AFC-DEVDase assay, as described under 'Materials and methods'. Data represent means7s.e. of three independent experiments. Statistical analysis was performed by Student's t-test, and Po0.05 was considered significant. (d) Immunoblot analysis for protein expression of the pro-and active forms of caspase-3 and -8. For caspase-9, the antibody detects only the active form. The cell lysate was prepared following treatment, and 50 mg of protein was subjected to 12% Tris-glycine gel electrophoresis, followed by immunoblot analysis and chemiluminescence detection, as described under 'Materials and methods'. The data shown here are representative of three independent experiments with similar results
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at 10 mg/ml, 32% at 20 mg/ml and 18% at 40 mg/ml, as compared to EGCG alone treatment ( Figure 5b ).
We next investigated the effect of caspase inhibitor and EGCG on the extent of caspase activation. Preincubation of cells with Z-VAD-FMK resulted in significant decrease in caspase activity. As observed by a comparison to the corresponding control (10-, 20-and 40-mg/ml EGCG concentration), a significant decrease (1.5-, 1.7-and 1.6-fold) in caspase activity was observed with Z-VAD-FMK treatment ( Figure 5c ). Immunoblot analysis further confirmed the results, where a significant decrease in the protein expression of the active products of caspase-3, -8 and -9 was observed by the pre-incubation of A431 cells with the Z-VAD-FMK caspase inhibitor. No significant modulation in the protein expression of caspase-3, -8 and -9 was observed in the Z-VAD-FMK treatment group (Figure 5d ). In addition to Z-VAD-FMK, we also used the caspase-3-specific inhibitor Z-DVED-FMK to assess the involvement of caspase-3 during EGCG-mediated apoptosis. Compared to control, pre-incubation of A431 cells with Z-DVED-FMK exhibited increased cell growth and inhibition of apoptosis, but the effects were moderate in comparison to the general caspase inhibitor Z-VAD-FMK (data not shown).
We next quantified the extent of apoptosis by flow cytometry, exhibiting 13 and 17% of TUNEL-positive cells at 20-and 40-mg/ml concentrations of EGCG, which were considerably reduced to 4.5 and 9.3%, as a result of the treatment of cells with Z-VAD-FMK ( Figure 6a ). The extent of apoptosis was further estimated by fluorescence microscopy using annexin-V-and PI-stained cells. As shown by the representative pictures (Figure 6b ), EGCG (20 and 40 mg/ml) treatment of A431 cells resulted in apoptosis at both the concentrations, as evidenced by chromatin condensation and nuclear condensation (20 mg/ml). The cells preincubated with Z-VAD-FMK exhibited few apoptotic cells at 20 and 40 mg/ml of EGCG. No apoptotic cells were observed in control and Z-VAD-FMK-treated groups (data not shown).
Inhibition of NF-kB increases EGCG-mediated apoptosis in A431 cells
In the next series of experiments, we investigated the effect of EGCG on the constitutive expression of NFkB/p65, NF-kB/p50 and IkBa in A431 cells. As shown by immunoblot analysis, EGCG treatment resulted in a dose-and time-dependent decrease in nuclear translocation of NF-kB/p65 protein expression, but not of the NF-kB/p50, as estimated in the nuclear fraction of these cells ( Figure 7a ). A similar effect was observed in cytosolic fraction, where EGCG treatment of cells leads to inhibition in the protein expression of NF-kB/p65 but not of NF-kB/p50 isomer (data not shown). The inhibition of NF-kB/p65 in the nuclear fraction correlated with the increase in the protein expression of IkBa in the cytosol, both in dose-and time-dependent fashion ( Figure 7a ), which was further confirmed by a more sensitive method that can detect NF-kB/p65 and recognize an epitope on p65 by ELISA. EGCGmediated inhibition of NF-kB/p65 expression was further correlated with increasing apoptosis in a dosedependent fashion (Figure 7b ). Similar results were observed by treatment of cells with 20 mg/ml of EGCG for different time intervals (Figure 7c ). These observations suggest the existence of two intriguing possibilities for the mechanism of EGCG-mediated NFkB inactivation and apoptosis: (i) EGCG may cause phosphorylative degradation of IkBa, thereby inhibiting the constitutive NF-kB expression, and (ii) modulation 
NF-kB DNA-binding activity and transcription is altered in EGCG-mediated apoptosis of A431 cells
Previous experiments have demonstrated that treatment of A431 cells with EGCG resulted in caspase activation, inhibition of NF-kB, and exhibit typical morphological and biochemical criteria for apoptosis. In the next series of experiment, we performed gel shift assays in control and EGCG-treated groups. As shown in Figure 8 , the control group exhibited binding of NF-kB/p65 to DNA, which was significantly increased by challenging the cells with TNF-a (positive control). In contrast, EGCG treatment to A431 cells exhibited a dose-and timedependent decrease in NF-kB/p65 DNA-binding activity (Figure 8a, b) . To determine the nature of difference in NF-kB complexes between control and EGCGtreated groups, we next performed supershift assays with antibodies against the NF-kB/p65 and NF-kB/p50 subunits of NF-kB. The EGCG-mediated responses in NF-kB complexes were mainly due to the NF-kB/p65 subunit (data not shown). These observations indicate that a molecular alteration of NF-kB/p65 may be responsible for EGCG-mediated apoptosis of A431 cells.
To test whether the induction of NF-kB-DNA-binding activity corresponds to an increase in NF-kB-dependent transcription, we transfected the cells with ELAM-specific luciferase (ELAM-Luc) reporter construct, having NF-kB-and AP-1-binding sites, and measured the increase in luciferase activity in control cells and after EGCG treatment. We used TNF-a-stimulated cells at a dose of 25 ng/ml as a positive control throughout the studies. Although ELAM-specific transcription is low in control cells, EGCG-treated cells exhibited a significant dose-and time-dependent decrease in transcriptional activity (Figure 8c, d ).
NF-kB/p65 is cleaved by caspases during EGCG-mediated apoptosis of A431 cells
To characterize the molecular changes occurring in the NF-kB complex during EGCG-mediated apoptosis, we analysed the NF-kB/p65 subunit. Since previous studies have shown RelA/p65 as a substrate for activated caspase that leads to the loss of carboxy-terminal transactivation domain of active NF-kB/p65 (Levkau et al., 1999) , we asked whether EGCG treatment leads to caspase-mediated cleavage of NF-kB/p65 subunit in A431 cells. For this, we have used a commercially available anti-p65 antibody that crossreacts with a protein of approximately B54 kDa specific to detect the cleavage of NF-kB/p65 at the carboxy-terminal transactivation domains. Studies have shown that B54 kDa protein (DN p65) is recognized by this antibody raised against amino acids 3-19 at the amino terminus of p65; therefore, it is likely that this protein is a C-terminally truncated p65 molecule, specifically observed in apoptotic cells (Levkau et al., 1999) . As shown by immunoblot analysis, EGCG treatment resulted in a dose-and time-dependent increase in the B54 kDa (DN p65) protein in the cytosolic fraction, suggesting that NF-kB/p65 may be cleaved during EGCG-mediated caspase activation and subsequent apoptosis of A431 cells (Figure 9a, b) . This cleavage leads to the loss of carboxy-terminal transactivation domains of NF-kB/ p65, and this may act as a dominant-negative inhibitor of NF-kB, promoting EGCG-mediated apoptosis. EGCG treatment resulted in dose-dependent increase in caspase activation which correlated with DN p65 protein expression, the cleaved product of NF-kB/p65 (Figure 9c) . Similar results were observed by treatment 
Inhibition of caspases increases EGCG-mediated constitutive expression, and nuclear localization of NFkB/p65 and IkBa in A431 cells
To further examine the effect of EGCG-mediated NFkB inhibition and induction of caspase-dependent apoptosis, A431 cells were incubated with Z-VAD-FMK prior to EGCG treatment. As shown in Figure  10a , pre-incubation of cells with Z-VAD-FMK resulted in a significant increase in the protein expression of NF-kB/p65 in the nuclear extract, as observed by immunoblot analysis. Further, increase of NF-kB/p65 expression in the nuclear fraction of A431 cells preincubated with Z-VAD-FMK correlated with a decrease in the protein expression of IkBa in the cytosol ( Figure  10a ). These results were further confirmed by more sensitive NF-kB/p65 ELISA in the nuclear extract (Figure 10b ). In the next series of experiments, we examined the dose-dependent effect of the caspase inhibitor on EGCG-mediated NF-kB/p65 inhibition of A431 cells. As shown in Figure 10c , pre-incubation of Z-VAD-FMK (10-40 mM) resulted in a dose-dependent increase in the protein expression of NF-kB/p65 in the nuclear fraction of EGCG (40-mg/ml)-treated A431 cells. The increase of NF-kB/p65 expression in the nuclear fraction of A431 cells pre-incubated with Z-VAD-FMK correlated with a dose-dependent decrease in the protein expression of IkBa in the cytosol. These results were further confirmed by more sensitive NF-kB/p65 ELISA in the nuclear extract (Figure 10d ).
Inhibition of caspases increases EGCG-mediated DNAbinding activity and transcription of NF-kB in A431 cells
We next investigated the effect of EGCG-mediated NFkB DNA-binding activity and its effect on caspase inhibition. As shown in Figure 11a , pre-incubation of cells with 10 mM concentration of Z-VAD-FMK resulted in a modest increase in the DNA-binding activity compared to the corresponding EGCG-treated group. (a) Dose-dependent and (b) time-dependent effect of EGCG on cleavage of NF-kB/p65, as observed by the cleaved product at B54 kDa, raised against amino acids 3-19 at the amino terminus of NF-kB/p65. Cells were treated at the indicated dose and times with EGCG. Negative control: Cells were stimulated with 25 ng/ml of TNF-a for 4 h. Positive control: Cells were treated with camptothecin with 5 mg/ml for 12 h. The details are described in 'Materials and methods' section. (c) Dose-dependent and (d) time-dependent increase in EGCG-mediated caspase activation causes cleavage of the NF-kB/p65 subunit. The data are compared between the fold increase in caspase activity, as shown in a previous experiment, versus increase in protein expression of DN p65, the cleaved product at B54 kDa, raised against amino acids 3-19, at the amino terminus of NF-kB/p65 Immunoblot analysis of NF-kB/p65 in nuclear extract and IkBa in cytoplasmic extract. Cells were incubated with 10 mM concentration of the general caspase inhibitor Z-VAD-FMK for 2 h, followed by addition of the indicated doses of EGCG. The nuclear and cytoplasmic lysates were subjected to 12% Tris-glycine gel electrophoresis, followed by immunoblot analysis and chemiluminescence detection, as described under 'Materials and methods'. The data shown here are representative of three independent experiments with similar results. (b) NF-kB/p65 activation by ELISA. (c) Cells were incubated with increasing concentration of the general caspase inhibitor Z-VAD-FMK for 2 h, followed by 40 mg/ml of EGCG treatment. Immunoblot analysis of NF-kB/p65 in nuclear extract and IkBa in cytoplasmic extract. (d) NF-kB/p65 activation by ELISA. The details are described in 'Materials and methods' section. Data represent means7s.e. of three independent experiments. Statistical analysis was performed by Student's t-test, and Po0.05 was considered significant
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We initially tested the effect of the caspase inhibitor Z-VAD-FMK on the constitutive expression of NF-kB/ p65, nuclear localization and DNA-binding activity following EGCG treatment. Further, we wanted to know if the caspase inhibition leads to survival of cells from EGCG-mediated apoptosis, which is linked to NFkB. To address this issue, the A431 cells were transfected with ELAM-Luc plasmids and were incubated with Z-VAD-FMK prior to EGCG treatment. Treatment of A431 cells with EGCG resulted in significant decrease in ELAM-specific luciferase activity, suggesting the role of NF-kB in cell survival. Further, pre-incubation of cells with Z-VAD-FMK (10 mM) resulted in 1.2-and 1.6-fold induction in ELAM-specific luciferase activity at 20 and 40 mg/ml of EGCG (Figure 11c ). The dose-dependent effect of caspase inhibitor (10-40 mM) resulted in a significant induction (1.6-fold at 10 mM, 1.9-fold at 20 mM and 3.2-fold at 40 mM Z-VAD-FMK) in EGCGmediated ELAM-specific luciferase activity ( Figure  11d ), which seems to play a role in cell survival. This effect was of a magnitude almost similar to that elicited by TNF-a, a well-characterized activator of NF-kB.
Inhibition of caspases decreases cleavage of NF-kB/p65 and increases survival of A431 cells
We initially tested the effect of caspase inhibitor Z-VAD-FMK on the constitutive expression of NF-kB, nuclear localization, DNA-binding activity and transcription following EGCG treatment. Further, we wanted to Immunoblot analysis of NF-kB DNA binding in the nuclear extract by EMSA, with increasing concentration of caspase inhibitor. Cells were incubated with increasing concentrations of the general caspase inhibitor Z-VAD-FMK for 2 h, followed by 40 mg/ml of EGCG treatment, as described under 'Materials and methods'. Positive control: biotin end-labeled target DNA with extract, negative control: biotin end-labeled target DNA with extract and a 200-fold molar excess of unlabeled DNA. (c) Reporter assay in A431 cells transfected with NF-kB-dependent ELAM-Luc construct having NF-kB-and AP-1-binding sites. Cells were incubated with 10 mM concentration of the general caspase inhibitor Z-VAD-FMK for 2 h, followed by addition of the indicated doses of EGCG. Luciferase activity normalized to b-galactosidase activity was determined 24 h after EGCG treatment, as described under 'Materials and methods'. Values are represented as fold induction. (d) Reporter assay in A431 cells transfected with NF-kB-dependent ELAM-Luc construct with increasing concentrations of caspase inhibitor. Cells were incubated with increasing concentration of the general caspase inhibitor Z-VAD-FMK for 2 h, followed by 40 mg/ ml of EGCG treatment. Luciferase activity normalized to bgalactosidase activity was determined 24 h after EGCG treatment, as described under 'Materials and methods'. Values are represented as fold induction. Control: Cells were stimulated with 25 ng/ml of TNF-a for 4 h with or without addition of EGCG. The data represent means7s.e. of three independent experiments. Statistical analysis was performed by Student's t-test, and Po0.05 was considered significant
Role of caspases in EGCG-induced apoptosis S Gupta et al know whether caspase activation is related to NF-kB inhibition during EGCG-mediated apoptosis of A431 cells. To address this issue, the cells were incubated with caspase inhibitor Z-VAD-FMK prior to EGCG treatment, and probed for the cleaved product of NF-kB/p65 subunit. As shown by immunoblot analysis, pre-incubation of cells with Z-VAD-FMK resulted in significant decrease in DN p65, the cleaved B54 kDa protein expression in the cytosolic fraction compared with the EGCG-treated groups (Figure 12a ). The dose-dependent effect of caspase inhibitor (10-40 mM) resulted in a significant decrease in DN p65 protein expression compared to the EGCG-treated group (Figure 12b ). These observations suggest that decrease in EGCGmediated caspase activation leads to inhibition of proteolytic cleavage of NF-kB/p65 and subsequent apoptosis. These results could be partially explained by the gelshift and transcription assays, where a modest increase in DNA-binding activity and transcription was observed after treatment with caspase inhibitor. We next asked whether modulation in NF-kB/p65 activation and cleavage by caspase inhibition leads to survival of cells from EGCG-mediated apoptosis. To examine this effect, we incubated A431 cells with Z-VAD-FMK with or without EGCG, and determined its effect on cell survival by trypan blue exclusion assay and apoptosis by ELISA, as previously described. Preincubation of cells with Z-VAD-FMK prior to EGCG treatment resulted in increase in the number of survival cells with concomitant decrease in apoptosis (data not shown). Further, a dose-dependent effect was observed with caspase inhibitor Z-VAD-FMK (data not shown). Next, we performed PARP cleavage assay in A431 cells incubated with Z-VAD-FMK prior to EGCG treatment. As shown in Figure 12c , pre-incubation of cells with Z-VAD-FMK resulted in decrease in cleavage of PARP compared to EGCG treatment. Further, a dosedependent decrease in PARP cleavage was observed in cells pre-incubated with 10-40 mM concentrations of Z-VAD-FMK (Figure 12d ). No cleavage of PARP was observed in cells treated with Z-VAD-FMK alone (Figure 12c, d) . These results indicate that cells could be rescued from apoptosis by pretreatment with caspase inhibitor Z-VAD-FMK, conferring an essential role of caspases in EGCG-mediated inhibition of NF-kB and induction of apoptosis.
Discussion
In recent years, green tea, specifically its major constituent EGCG, has gained much attention due to its cancer chemopreventive properties. A significant reason for the great interest in EGCG is because of its remarkable effects in many in vitro and in vivo tumor model systems Singh et al., 2002; Chung et al., 2003; Gupta et al., 2003; Hastak et al., 2003) . Part of this effect of EGCG appears to be because, at physiologically attainable concentrations, it induces apoptosis in cancer cells without affecting normal cells (Ahmad et al., 1997, 2000 ; Chen et al., 1998). Our earlier studies have shown that EGCG treatment of cancer cells resulted in a dose-dependent (i) inhibition of cell growth, (ii) G0/G1 phase arrest of the cell cycle and (iii) induction of apoptosis (Ahmad et al., 1997; Gupta et al., 2003) . Apoptosis represents a universal and exquisitely efficient suicide pathway, an ideal way for elimination of damaged cells (Ferreira et al., 2002) . The apoptotic process may conceptually be and DN p65, the cleaved product at B54 kDa, raised against amino acids 3-19 at the amino terminus of NF-kB/p65. Cells were incubated with increasing concentration of the general caspase inhibitor Z-VAD-FMK for 2 h, followed by 40 mg/ml of EGCG treatment, as described under 'Materials and methods'. (c) Immunoblot analysis of PARP cleavage. Cells were incubated with 10 mM concentration of general caspase inhibitor Z-VAD-FMK for 2 h, followed by addition of the indicated doses of EGCG. The cell lysates were prepared following treatment, and 50 mg of protein was subjected to 12% Tris-glycine gel electrophoresis, followed by immunoblot analysis and chemiluminescence detection, as described under 'Materials and methods'. The data shown here are representative of three independent experiments with similar results. (d) Immunoblot analysis of PARP cleavage with increasing concentration of caspase inhibitor. Cells were incubated with increasing concentration of the general caspase inhibitor Z-VAD-FMK for 2 h, followed by 40 mg/ml of EGCG treatment. The cell lysates were prepared following treatment, and 50 mg of protein was subjected to 12% Tris-glycine gel electrophoresis, followed by immunoblot analysis and chemiluminescence detection, as described under 'Materials and methods'. The data shown here are representative of three independent experiments with similar results
Role of caspases in EGCG-induced apoptosis S Gupta et al divided into three phases: an induction phase, the nature of which depends on the specific death-inducing signals, an effector phase, during which the central executioner is activated, and a degradation phase that leads to morphological features of end-stage apoptosis (Nicholson, 1999; Grutter, 2000; Zimmermann et al., 2001) . Since the execution machinery of apoptosis appears to be evolutionarily conserved, it seems possible that it plays an especially important role in governing both the accuracy and efficiency of the apoptotic pathway. The execution phase occurs through the activation and function of caspases, which cleave certain critical targets leading to apoptosis (Lazebnik et al., 1995; Tewari et al., 1995; Janicke et al., 1996; Cheng et al., 1997; Clem et al., 1998; Tang and Kidd, 1998; Levkau et al., 1999; Stennicke and Salvesen, 2000) . Many investigators have studied the signaling pathway in the initiation and propagation of various chemopreventive agents; however, the execution phase has not been well studied (Clement et al., 1998; Yu et al., 1998) . Our present study provides an essential role of caspases as the executionary phase in EGCG-mediated apoptosis. Caspases are part of a growing family of cysteine proteases that have been shown to be involved in many forms of apoptosis (Nicholson, 1999; Grutter, 2000; Zimmermann et al., 2001) . Activation of caspase proteases was previously shown to be required for the induction of apoptosis in different cell types (Islam et al., 2000; Hayakawa et al., 2001) . Caspases are activated as a consequence of cell membrane signaling events that can be classified as initiating or upstream caspases. Several caspases (caspase-2, -8 and -10) have large prodomain-containing motifs for protein-protein interactions, allowing for their interaction with activation by proteins associated with cytoplasmic domains of the family of death receptors. Recent studies on receptormediated apoptosis and activation of caspase-8 is the earliest event, which is synthesized as inactive proenzymes activated by proteolytic cleavage after specific aspartate residue, and is capable of activating downstream caspases (Kim et al., 2001 ). The effector, or downstream caspase (caspase-3, -6 and -7), is activated later than the upstream caspases. These effectors or downstream caspases have been defined as a key executioner involved in the apoptosis induced by various stimuli, and is also necessary for nuclear changes associated with apoptosis, such as chromatin condensation and PARP cleavage (Nicholson, 1999; Grutter, 2000; Stennicke and Salvesen, 2000) . In the present study, we have shown that caspase-3, -8 and -9 are activated during EGCG-mediated apoptosis. Our studies have further shown that addition of Z-VAD-FMK, a general caspase inhibitor, significantly reduces EGCG-mediated apoptosis, while inhibition of caspase-3 by Z-DVED-FMK resulted in only partial prevention of apoptosis. Inhibitory effects of Z-VAD-FMK and Z-DVED-FMK provide evidence that EGCG-mediated apoptosis in A431 cells is caspase dependent.
We have previously demonstrated the involvement of NF-kB in regulating EGCG-mediated apoptotic response of cancer cells . NF-kB has been implicated in a number of cellular functions, including cell survival, proliferation and apoptosis. Numerous studies have shown that NF-kB regulates susceptibility of cells to apoptosis through the transcriptional control of genes (Bours et al., 2000; Joyce et al., 2001; Karin and Lin, 2002) . Inhibition of NF-kB and nuclear translocation has been shown to increase the susceptibility of cells to undergo apoptosis induced by TNF-a, LPS, ionizing radiation and anticancer agents (Wang et al., 1996; Bours et al., 2000; Joyce et al., 2001; Karin and Lin, 2002) . Recent studies have demonstrated that suppression of NF-kB activation by protease inhibitors could block IkBa degradation-induced apoptosis (Wu et al., 1996) . Further, ectopic expression of cRel was found to ablate the induction of apoptosis following suppression of NF-kB activation by inhibitors of IkBa degradation (Wu et al., 1996) . These findings point to a critical role of NF-kB and essential role of caspases in apoptotic cell death. In the present study, we have demonstrated that EGCG-mediated caspase activation leads to constitutive NF-kB inhibition and subsequent apoptosis of human epidermoid carcinoma A431 cells. The maintenance of NF-kB activity by the cells is required for cell survival and, conversely, inhibition in the constitutive activity directs the cells towards apoptosis. The inhibition of NF-kB transcriptional activity observed during EGCG-mediated apoptosis could be the result of two distinct inhibitory mechanisms: first, blockade of IkB degradation, and second, cleavage of NF-kB subunit that may disable the transactivation capacity. Our studies have identified the NF-kB/p65 component of the NF-kB complex as a target for specific cleavage by caspases during EGCGmediated apoptosis. This cleavage leads to the loss of carboxy-terminal transactivation domains of NF-kB/ p65, resulting in truncated p65 and promoting apoptosis. Further, pre-incubation of Z-VAD-FMK prior to EGCG treatment was found to result in the increase in cell survival, as observed by modest increase in constitutive NF-kB expression, DNA binding and transcriptional activity. This observation leads to the confirmation that, as long as the cells are capable of maintaining transcriptionally active NF-kB, they are able to resist EGCG-mediated apoptotic cell death. The fact is that EGCG-induced caspase activation leads to cleavage of NF-kB/p65 and subsequently decreases cell transcription that may be aborted by pre-incubation of A431 cells with the general caspase inhibitor Z-VAD-FMK. Whether suppression of NF-kB activation is responsible for initiation of EGCG-mediated apoptosis in A431 cells is further supported by the observation that transfection of cells with a NF-kB-dependent reporter construct (ELAM-Luc) having NF-kB-and AP-1-binding sites resulted in significant decrease in ELAM-specific luciferase activity. Importantly, preincubation of Z-VAD-FMK was found to result in the increase in EGCG-mediated ELAM-specific luciferase activity. Similar effects were observed on human epithelial prostate carcinoma LNCaP cells (data not shown). These findings point to a critical role of caspases in modulating NF-kB family members in cell survival and cell death, which is not cell type specific. These data further suggest that the apoptotic program elicited by EGCG in cancer cells can destroy NF-kB through an elegant and efficient caspase-mediated switch-off mechanism that commits the cells towards apoptosis. The schematic representation of the action of EGCG is depicted in Figure 13 .
A number of pathways have been suggested that may lead to program cell death by chemopreventive agents . In this aspect, two central pathways have been shown to be involved in the process of apoptotic cell death: one shows the direct involvement of caspase proteases (especially caspase-8) and, the other, the mitochondrial pathway where caspases are activated as downstream events in apoptosis (Green and Kroemer, 1998) . The molecular ordering of caspases has been upheld in several cases, and is best exemplified by caspase-8-mediated activation of caspase-3 and -7 in the CD95/Fas/APO-1 system, and caspase-9-mediated activation of caspase-3 in the Apaf-1/cytochrome c pathway (Nicholson, 1999) . Recent studies from our group have demonstrated the role of EGCG in disruption of mitochondrial pathway and induction of apoptosis (Hastak et al., 2003) . The role of EGCG in the activation of death receptor Fas/APO-1 has been recently demonstrated by another group (Kuo and Lin, 2003) . However, this study and the pathways that lead to EGCG-induced apoptosis described herein are novel and have not been elucidated. Experimental evidence has further shown CD95/Fas-induced caspase-mediated proteolysis of NF-kB, suggesting a link between NF-kB and programmed cell death or apoptosis (Ravi et al., 1998) . This phenomenon leads to the existence of multiple distinct apoptotic mechanisms for the inactivation of NF-kB, and further support the idea that its inactivation has a central role in the commitment to apoptosis. Additional studies are needed to identify different caspase cleavage sites on NF-kB that are involved in EGCG-mediated apoptosis. It is important to emphasize here that caspase activity varies according to the cell type and apoptotic stimuli. Since induction of apoptosis is considered an important mechanism of prevention/treatment of cancer by chemopreventive agent(s), further elucidation of the mechanism via different signaling pathways during EGCG-mediated apoptosis would provide useful information concerning the basis for its use as a potential therapeutic agent.
Materials and methods
Materials
A purified preparation of EGCG (498% pure) was kindly provided by Dr Yukihiko Hara of Mitsui Norin Co., Ltd (Shizuoka, Japan). Antibody for casapase-3 was purchased from Upstate Biotechnology (Lake Placid, NY, USA), caspase-8 from Biosource International (Camarillo, CA, USA) and caspase-9 from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). NF-kB/p65 and NF-kB/p50 antibodies were obtained from Geneka Biotechnology Inc. (Montreal, Canada). Another NF-kB/p65 antibody used for the studies was obtained from Santa Cruz Biotechnology, Inc. that recognizes both NF-kB/p65 subunit and the cleaved product at B54 kDa, raised against amino acids 3-19 at the amino terminus of NF-kB/p65. The antibody for IkBa was purchased from New England Biolabs, Inc. 
Cell culture
The human epidermoid carcinoma (A431) and androgensensitive human prostate carcinoma LNCaP cells were obtained from American Type Culture Collection (ATCC) (Rockville, MD, USA). The cells were cultured under standard culture condition in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. The cells were maintained at 371C and 5% CO 2 in a humid environment.
Treatment of cells
EGCG was dissolved in PBS (pH 7.4) and employed for the treatment of cells. The cells were treated with 10-, 20-and 40-mg/ml concentrations for 24 h. For DNA fragmentation and PARP cleavage, the cells were treated with the desired doses of EGCG for 48 h. For time-dependent assay, the cells were treated with 20 mg/ml of EGCG for 12, 24 and 48 h, respectively. For caspase-inhibition experiments, the cells were incubated with Z-VAD-FMK or Z-DEVD-FMK at the desired concentration for 2 h before addition of EGCG. At 24 h after the addition of EGCG, cells were harvested and processed for trypan blue exclusion assay, ELISA and TUNEL assay or immunoblot analysis.
Cell viability
The cells were grown to 70% confluence and treated with EGCG (10, 20, and 40 mg/ml) for 24 h, and the cell viability was determined by trypan blue exculsion assay.
Apoptosis by ELISA
Following EGCG treatment, the extent of apoptosis was determined by Cell Death Detection ELISA PLUS assay, according to the manufacturer's protocol. Briefly, the cells were harvested after EGCG treatment at 10-, 20-and 40-mg/ml doses and 12, 24 and 48 h time intervals, and incubated on ice for 30 min in Tris lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 20 mM NaF, 0.5% NP-40, 1% Triton X-100) containing fresh protease inhibitors (5 mg/ml, aprotinin, 10 mg/ml phenylmethylsulfonyl fluoride and 10 mg/ ml sodium vanadate), and then centrifuged at 12 000 r.p.m. for 10 min at 41C. The total cell lysate was used for protein determination by the DC BioRad s protein assay. The lysate (30 mg of total protein) was added to the lysis buffer and pipetted on a streptavidin-coated 96-well microtiter plate to which the immunoreagent mix was added and incubated for 2 h at room temperature, with continuous shaking at 500 r.p.m. The wells were then washed with washing buffer, the substrate solution added, the color developed (10-20 min) was read at 405 nm against the blank, reference wavelength of 490 nm. The enrichment factor (total amount of apoptosis) was calculated by dividing the absorbance of the sample (A405 nm) by the absorbance of the controls without treatment (A490 nm).
DNA fragmentation assay
Following treatment of cells as described above, the cells were washed twice with PBS (pH 7.4), incubated with DNA lysis buffer (10 mM Tris, pH 7.5, 400 mM NaCl, 1 mM EDTA and 1% Triton X-100) for 30 min on ice and then centrifuged at 14 000 Â g at 41C. The supernatant obtained was incubated overnight with RNAse (0.2 mg/ml) at room temperature and then with Proteinase K (0.1 mg/ml) for 2 h at 371C. DNA was extracted using phenol : chloroform (1 : 1) and precipitated with 95% ethanol for 2 h at À801C. The DNA precipitate was centrifuged at 14 000 g at 41C for 15 min and the pellet was airdried and dissolved in 20 ml of Tris-EDTA buffer (10 mM TrisHCl, pH 8.0 and 1 mM EDTA). The total amount of DNA was resolved over 1.5% agarose gel, containing 0.3 mg/ml ethidium bromide in 1 Â TBE buffer (pH 8.3, 89 mM Tris, 89 mM boric acid and 2 mM EDTA) (Bio Wittaker, Inc., Walkersville, MD, USA). The bands were visualized under a UV transilluminator (Model # TM-36, UVP Inc., San Gabriel, CA, USA) followed by polaroid photography (MP-4 Photographic System, Fotodyne Inc., Hartland, WI, USA).
Apoptosis by flow cytometry
The cells were grown at a density of 1 Â 10 6 cells in 100-mm culture dish, and were treated with EGCG (10-, 20-and 40-mg/ ml concentration) for 24 h and 20 mg/ml EGCG for 12-48 h. The cells were trypsinized, washed with PBS and processed for labeling with fluorescein-tagged bromodeoxyuridine triphosphate (Br-dUTP) and propidium iodide, using the APO-BRDU apoptosis kit, as per the manufacturer's protocol. The labeled cells were then analysed by flow cytometry.
Caspase activity assay
The activity of caspases was measured by the fluorometric assay, following the manufacturer's protocol. Briefly, cells treated with EGCG and/or caspase inhibitors followed their lysis using lysis buffer (0.1 M HEPES buffer, pH 7.4, containing 2 mM DTT, 0.1% Chaps and 1% sucrose). Cell lysates were incubated with 10 ml of 100 mM fluorogenic substrates, Ac-DEVD-AFC (Ac-Asp-Glu-Val-Asp-AFC), purchased from Calbiochem (San Diego, CA, USA) for 30 min at 301C. This is a fluorogenic caspase-3 substrate, and also acts as a substrate for granzymeB-processed ICE-LAP3, caspase-6, -7, -8 and -10. The release of AFC was measured with a fluorescence spectrophotometer at 400-nm excitation and 505-nm emission.
Protein extraction and immunoblot analysis
Following the treatment of cells as described above, the media was aspirated, the cells were washed with cold PBS (pH 7.4), and ice-cold lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 20 mM NaF, 100 mM Na 3 VO 4 , 0.5% NP-40, 1% Triton X-100, 1 mM PMSF (pH 7.4)) with freshly added protease inhibitor cocktail (Protease Inhibitor Cocktail Set III, Calbiochem, La Jolla, CA, USA) was added and it was incubated over ice for 30 min. The cells were scraped, the lysate was collected in a microfuge tube and passed through a 21 1 2 G needle to break up the cell aggregates. The lysate was cleared by centrifugation at 14 000 g for 15 min at 41C, and the supernatant (total cell lysate) was used or immediately stored at À801C. For NF-kB/p65 assay, the cells were processed for nuclear and postnuclear fractions, as described previously . The protein concentration was determined by DC Bio-Rad assay using the manufacturer's protocol (Bio Rad Laboratories, Hercules, CA, USA).
For immunoblot analysis, an appropriate amount of cell lysates (25-50 mg protein) was resolved over 12% Tris-Glycine polyacrylamide gel and then transferred onto the nitrocellulose membrane. The blots were blocked using 5% non-fat dry milk and probed using appropriate primary antibodies in blocking buffer overnight at 41C. The membrane was then incubated with the appropriate secondary antibody horseradish peroxidase (HRP) conjugate (Amersham Life Sciences Inc., Arlington Heights, IL, USA), followed by detection using a chemiluminescence ECL kit (Amersham Life Sciences Inc., Arlington Heights, IL, USA). For equal loading of protein, the membrane was stripped and reprobed with an anti-b-actin antibody.
ELISA assay for NF-kB activity ELISA was performed for NF-kB/p65 activity, according to the vendor's protocol. This assay uses an oligonucleotide containing NF-kB consensus site (5 0 -GGGACTTTCC-3 0 ) that binds to the cell extract and can detect NF-kB, which can recognize an epitope on p65 activated and bound to its target DNA. This assay is specific for NF-kB/p65 activation, and is highly sensitive when compared with the gel-retardation technique.
Electrophoretic mobility shift assay (EMSA) and Supershift assay EMSA for NF-kB was performed using lightshiftt chemiluminiscent EMSA kit (Pierce, Rockford, IL, USA), following the manufacturer's protocol. Briefly, DNA was biotin labeled using the biotin 3 0 end-labeling kit (Pierce, Rockford, IL, USA) in a 50 ml reaction buffer, 5 pmol of double-stranded NF-kB oligonucleotide (5 0 -AGTTGAGGGGACTTTCC CAGGC-3 0 and 3 0 -TCAACTCCCCTGAAAGGGTCCG-5 0 ) incubated in a microfuge tube with 10 ml of 5 Â terminal deoxynucleotidyl transferase (TdT) buffer, 5 ml of 5 mM biotin-N4-CTP, 10 U of diluted TdT and 25 ml of ultrapure water at 371C for 30 min. The reaction was stopped with 2.5 ml of 0.2 M EDTA. To extract labeled DNA, 50 ml of chloroform : isoamyl alcohol (24 : 1) was added to each tube and centrifuged at 13 000 g. The top aqueous phase containing the labeled DNA was further used for binding reactions. Each binding reaction contained 1 Â binding buffer (100 mM Tris, 500 mM KCl, 10 mM dithiothreitol, pH 7.5), 2.5% glycerol, 5 mM MgCl 2 , 50 ng/ml poly (dI-dC), 0.05% NP-40, 2.5 mg of nuclear extract and 20-50 fm of biotin end-labeled target DNA. The contents were incubated at room temperature for 20 min. To this reaction mixture, 5 ml of 5Â loading buffer was added, subjected to gel electrophoresis on a native polyacrylamide gel and transferred to a nylon membrane. After transfer was completed, DNA was crosslinked to the membrane at 120 mJ/cm 2 using a UV crosslinker equipped with 254-nm bulb. The biotin end-labeled DNA was detected using streptavidin-horseradish peroxidase conjugate and a chemiluminiscent substrate. The membrane was exposed to an X-ray film (XAR-5 Amersham Life Science Inc., Arlington Height, IL, USA) and developed using a Kodak film processor. For supershift assay, antibodies against NF-kB/p65 and NF-kB/ p50 were added 30 min after beginning of the reaction, and incubation was continued for an additional 30-45 min. DNA protein complexes were analysed as described earlier.
Fluorescence microscopy
The cells were treated as described earlier, and washed with PBS and resuspended and incubated with 100 ml of staining solution for 10-15 min at room temperature. The mixture was then placed on the stage of Zeiss Axiovert 100 microscope. The samples were excited at 330-380 nm, and the image was observed and photographed under a combination of a 400-nm dichoric mirror and then a 420-nm high-pass filter. Apoptotic and necrotic cells were scored under the microscope. Cells with green, condensed chromatin pattern were considered apoptotic, whereas those with orange nuclei without nuclear condensation were considered necrotic.
Transfection and reporter assay
The NF-kB-dependent reporter plasmid (ELAM-Luc) having NF-kB-and AP-1-binding sites, and CMV-b-gal plasmid, were obtained as a kind gift from Dr Munna L Agarwal (Cleveland Clinic Foundation, Cleveland, OH, USA). The A431 cells were transiently transfected using Fugene 6 reagent with 1.5 mg ELAM-Luc and 1 mg of CMV-b-gal plasmid. After 24 h, the media was changed and cells were treated with the desired concentration of Z-VAD-FMK 2 h, prior to EGCG addition. For positive control, the cells were stimulated with 25 ng/ml of TNF-a (Roche, Indianapolis, IN, USA) for 4 h with or without addition of EGCG. After treatment with EGCG for 24 h, luciferase and galactosidase activity was determined with the luciferase assay system and b-galactosidase assay system (Promega, Madison, WI, USA), according to the vendor's protocol. Luciferase activity was normalized to b-galactosidase activity to control for transfection efficiency.
Statistical analysis
The enzyme activity and other values are expressed as mean7s.e. The significance values between the control and treated groups were calculated by the Student's 't'-test, and Pvalues less than 0.05 were taken as significant in all the experiments.
Abbreviations EGCG, (À)-epigallocatechin-3-gallate; NF-kB, nuclear factorkappaB; PARP, poly(ADP-ribose) polymerase; Z-VAD-FMK, N-benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone; Z-DEVD-FMK, CPP32/apopain inhibitor.
